Document Detail


Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides.
MedLine Citation:
PMID:  12756099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To assess the safety and tolerability of a topical gel formulation combining methotrexate and laurocapram and to obtain preliminary information on the therapeutic potential of methotrexate-laurocapram in patients with early-stage mycosis fungoides (stage IA or IB). DESIGN: An open-label, phase 1/2 pilot study. SETTING: Two academic referral centers. PATIENTS: Ten patients 18 years or older with histologically confirmed stage IA or IB mycosis fungoides. Intervention The gel formulation of methotrexate-laurocapram was applied to the total body surface, excluding genital, perianal areas, nipples, face, and skin under the breasts, on an every-other-day basis for 24 consecutive weeks. MAIN OUTCOME MEASURES: The safety of methotrexate-laurocapram was assessed in this study by reviewing adverse events and laboratory data. Efficacy outcomes included changes in lesion condition and severity assessments, reduction in area of sample lesions, and the investigator's global evaluation. RESULTS: Adverse events consisted of skin reactions of mild severity. No clinically significant laboratory abnormalities were observed. Based on the investigator's global evaluation at the end of the treatment phase (week 24), 7 (78%) of 9 patients demonstrated a slight-to-moderate response to treatment with methotrexate-laurocapram. Statistical significance (P =.049) was reached for induration and pruritus, a trend (P =.10) was observed for erythema, and no change was found for scaling (P =.37). CONCLUSIONS: These findings indicate that the topical administration of methotrexate-laurocapram is safe and in general well tolerated. This treatment may represent a new therapeutic potential for patients with mycosis fungoides.
Authors:
Marie-France Demierre; Luc Vachon; Vincent Ho; Lynda Sutton; Allen Cato; Brian Leyland-Jones
Related Documents :
22995089 - Transcatheter aortic valve implantation: new developments and upcoming clinical trials.
10589359 - Combination dmard therapy including corticosteroids in early rheumatoid arthritis.
19924799 - Methotrexate for maintenance of remission in chronic active crohn's disease: long-term ...
21375159 - Efficacy and safety of artemehter-lumefantrine in uncomplicated falciparum malaria in l...
24350569 - Preliminary experience with stenting for management of non-urolith urethral obstruction...
16377229 - Rheumatoid nodulosis. two cases with destructive polyarthritis after 20 years.
12434119 - Protein c, s and antithrombin iii levels in patients with acute mechanical valve thromb...
22275809 - The effect of intravitreal anti-vegf agents on peripheral wound healing in a rabbit model.
17585259 - Is it hazardous or mandatory to release the talocalcaneal interosseous ligament in club...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Archives of dermatology     Volume:  139     ISSN:  0003-987X     ISO Abbreviation:  Arch Dermatol     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-20     Completed Date:  2003-06-10     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  0372433     Medline TA:  Arch Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  624-8     Citation Subset:  AIM; IM    
Affiliation:
Skin Oncology Program, Department of Dermatology, Boston Medical Center, Boston University School of Medicine, 720 Harrison Avenue, Doctors Office Building 801A, Boston, MA 02118, USA. mariefrance.demierre@bmc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Azepines / administration & dosage,  adverse effects,  therapeutic use*
Dermatologic Agents / administration & dosage,  adverse effects,  therapeutic use*
Drug Combinations
Female
Follow-Up Studies
Gels
Humans
Male
Methotrexate / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Mycosis Fungoides / drug therapy*,  pathology
Neoplasm Staging
Pilot Projects
Skin Neoplasms / drug therapy*,  pathology
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Azepines; 0/Dermatologic Agents; 0/Drug Combinations; 0/Gels; 59-05-2/Methotrexate; 59227-89-3/laurocapram

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sentinel lymph node biopsy in patients with thin melanoma.
Next Document:  Rapidly growing mycobacterial infections after pedicures.